| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-07-08 | pembrolizumab - MK-3475 | gastric adenocarcinoma | 3 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2015-07-08 | guselkumab (CNTO 1959) | psoriasis | 2b | Janssen Research & Development, a J&J company (USA - NJ) | Autoimmune diseases - Dermatological diseases |
| 2015-07-07 | ImmunTraCkeR® and ipilimumab | melanoma | ImmunID (France) | Cancer - Oncology - Diagnostic | |
| 2015-07-06 | CAP®Go cell line | preclinical | CEVEC Pharmaceuticals (Germany) | Technology - Services - Inflammatory diseases - Neurodegenerative diseases | |
| 2015-07-06 | ThermoDox® (encapsulated doxorubicin) in combination with mild hypothermia | recurrent chest wall (RCW) breast cancer | 2 | Celsion (USA - NJ) | Cancer - Oncology |
| 2015-07-06 | PV-10 | hepatocellular carcinoma | 1 | Provectus Pharmaceuticals (USA - TN) | Cancer - Oncology |
| 2015-07-01 | TV-45070 (formerly XEN402) | osteoarthritis of the knee | 2 | Teva Pharmaceutical (Israel) Xenon Pharmaceuticals (Canada) | Inflammatory diseases - Rheumatic diseases |
| 2015-07-01 | apalutamide (ARN-509, JNJ-56021927) | prostate cancer | 3 | Aragon Pharmaceuticals (USA - CA), now Johnson&Johnson (J&J) (USA - NJ) | Cancer - Oncology |
| 2015-06-30 | hepatocellular carcinoma | Medivir (Sweden) | Cancer - Oncology | ||
| 2015-06-30 | tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) | metastatic colorectal cancer | 2 | Aveo Oncology (USA - MA) | Cancer - Oncology |
| 2015-06-29 | FT227 | pain | 1 | Flamel Technologies (France) | CNS diseases |
| 2015-06-26 | BioChaperone Lispro | type 1 diabetes | 1b | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-06-25 | OI320GT (NN1957) | type 2 diabetes | 1 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2015-06-24 | bryostatin | Niemann-Pick disease type C | preclinical | Neurotrope BioScience (USA - NJ) | Rare diseases - Genetic diseases |
| 2015-06-24 | metadoxine extended release (MDX) | fragile X syndrome | 2b | Alcobra (Israel) | Rare diseases - Genetic diseases |
| 2015-06-24 | PRO 140 | graft-versus-host disease (GvHD) | CytoDyn (Canada) | Immunological diseases - Transplantation | |
| 2015-06-24 | Envarsus® (previously LCP-Tacro™) (tacrolimus) | prevention of organ rejection in adult kidney transplant patients |
3 | Veloxis Pharmaceuticals (Denmark) | Transplantation |
| 2015-06-24 | NovoEight® (turoctocog alfa) | hemophilia A | 3 | Novo Nordisk (Denmark) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2015-06-23 | ZP4207 | severe hypoglycemia in Type 1 and Type 2 diabetes patients | 1 | Zealand Pharma (Denmark) | Metabolic diseases |
| 2015-06-23 | belinostat | peripheral T-cell lymphoma (PTCL) | 2 | Onxeo (France) Spectrum Pharmaceuticals (USA) | Cancer - Oncology |
